Cancer Res Treat.  2011 Mar;43(1):67-70.

Two Pediatric Osteosarcoma Cases with Delayed Methotrexate Excretion: Its Clinical Course and Management

• Lee KM
• Lee HW
• Kim SY
• Lee HJ
• Kim DH
• Cho J
• Kim DH
• Lim JS
• Lee JK
• Lee JA

Abstract

High-dose methotrexate (MTX) chemotherapy extends the duration of hospitalization and introduces the risks of serious complications related to delayed MTX excretion. The treatment of delayed MTX excretion is largely dependent on invasive measures such as hemodialysis because the clinical data regarding the efficacy or safety of carboxypetidase G2 is limited. We report here on the cases of two pediatric osteosarcoma patients with delayed MTX excretion and who were successfully managed using supportive measures. Potential life-threatening complications were prevented by administering high doses of leucovorin.

Keyword

Methotrexate; Osteosarcoma; Child; Complication; Management

MeSH Terms

Child
Hospitalization
Humans
Leucovorin
Methotrexate
Osteosarcoma
Renal Dialysis
Leucovorin
Methotrexate

Figure

• 

  Fig. 1 Correlation between the serum methotrexate (MTX) level and the serum creatinine level in the patient of case 1.

• 

  Fig. 2 Correlation between the serum methotrexate (MTX) level and the serum creatinine level in the patient of case 2.

Reference

1. Biswal BK, Verma RS. Differential usage of the transport systems for folic acid and methotrexate in normal human T-lymphocytes and leukemic cells. J Biochem. 2009; 146:693–703. PMID: 19692428.

2. Widemann BC, Adamson PC. Understanding and managing methotrexate nephrotoxicity. Oncologist. 2006; 11:694–703. PMID: 16794248.

3. Relling MV, Stapleton FB, Ochs J, Jones DP, Meyer W, Wainer IW, et al. Removal of methotrexate, leucovorin, and their metabolites by combined hemodialysis and hemoperfusion. Cancer. 1988; 62:884–888. PMID: 3261621.

4. Widemann BC, Hetherington ML, Murphy RF, Balis FM, Adamson PC. Carboxypeptidase-G2 rescue in a patient with high dose methotrexate-induced nephrotoxicity. Cancer. 1995; 76:521–526. PMID: 8625136.

5. Lawrenz-Wolf B, Wolfrom C, Frickel C, Fengler R, Wehinger H, Henze G. Severe renal impairment of methotrexate elimination after high dose therapy. Klin Padiatr. 1994; 206:319–326. PMID: 7967432.

6. Relling MV, Fairclough D, Ayers D, Crom WR, Rodman JH, Pui CH, et al. Patient characteristics associated with high-risk methotrexate concentrations and toxicity. J Clin Oncol. 1994; 12:1667–1672. PMID: 8040679.

7. Cassano WF. Serious methotrexate toxicity caused by interaction with ibuprofen. Am J Pediatr Hematol Oncol. 1989; 11:481–482. PMID: 2618985.

8. Delepine N, Delepine G, Cornille H, Brion F, Arnaud P, Desbois JC. Dose escalation with pharmacokinetics monitoring in methotrexate chemotherapy of osteosarcoma. Anticancer Res. 1995; 15:489–494. PMID: 7763028.

9. Bleyer WA. The clinical pharmacology of methotrexate: new applications of an old drug. Cancer. 1978; 41:36–51. PMID: 342086.

10. Abelson HT, Fosburg MT, Beardsley GP, Goorin AM, Gorka C, Link M, et al. Methotrexate-induced renal impairment: clinical studies and rescue from systemic toxicity with high-dose leucovorin and thymidine. J Clin Oncol. 1983; 1:208–216. PMID: 6607976.

11. Widemann BC, Balis FM, Murphy RF, Sorensen JM, Montello MJ, O'Brien M, et al. Carboxypeptidase-G2, thymidine, and leucovorin rescue in cancer patients with methotrexate-induced renal dysfunction. J Clin Oncol. 1997; 15:2125–2134. PMID: 9164227.

12. Meyers PA, Heller G, Healey J, Huvos A, Lane J, Marcove R, et al. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol. 1992; 10:5–15. PMID: 1370176.

13. Wall SM, Johansen MJ, Molony DA, DuBose TD Jr, Jaffe N, Madden T. Effective clearance of methotrexate using high-flux hemodialysis membranes. Am J Kidney Dis. 1996; 28:846–854. PMID: 8957036.

14. Djerassi I, Ciesielka W, Kim JS. Removal of methotrexate by filtration-adsorption using charcoal filters or by hemodialysis. Cancer Treat Rep. 1977; 61:751–752. PMID: 889610.

15. Saland JM, Leavey PJ, Bash RO, Hansch E, Arbus GS, Quigley R. Effective removal of methotrexate by high-flux hemodialysis. Pediatr Nephrol. 2002; 17:825–829. PMID: 12376811.